Double lung transplantation appears to offer superior survival outcomes to single lung transplantation in patients with interstitial pulmonary fibrosis who are younger than 70 years.
Recombinant human pentraxin 2 slows the decline in lung function for patients with idiopathic pulmonary fibrosisJune 19, 2018
The use of recombinant human pentraxin 2 vs placebo resulted in a slower decline in lung function over 28 weeks for patients with idiopathic pulmonary fibrosis. However, there were no significant treatment differences were observed in total lung volume, parenchymal features on high resolution CT, or diffusion capacity of carbon monoxide.
Several patients were treated for idiopathic pulmonary fibrosis were identified as dental personnel.
Lung disease experts Athol Wells, MD, and Joshua Mooney, MD, MS, debate the diagnostic value of bronchoalveolar lavage in idiopathic pulmonary fibrosis.
Specific guidelines should be developed for the use of the 6-minute walk test in idiopathic pulmonary fibrosis.
Depression and anxiety may affect quality of life for patients with idiopathic pulmonary fibrosis.